Clinical trial · Observational
Radiation Pneumonitis After SBRT for NSCLC
Lung Function After Curatively Intended Radiotherapy for Non-small-cell Lung Carcinoma, -Changes and Predictive Markers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aims: 1. Evaluate changes in lung function before and after radiotherapy for patients with NSCLC in stage I-III receiving curatively intended radiotherapy 2. To assess the predictive value of pulmonary function tests for the development of radiation pneumonitis after curative radiotherapy 3. To assess biomarkers in blood samples before, during, and after radiotherapy and correlate to the development of radiation pneumonitis 4. Investigate survival
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Function Changes | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic or conventional radiotherapy and chemotherapy in curative intent | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung cancer patients
- description
- Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent
- interventionNames
- Radiation: Stereotactic or conventional radiotherapy and chemotherapy in curative intent
Primary outcomes (1)
- measure
- permanently reduced lung function
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- predictive value of pulmonary function tests for the development of a permanent reduction in lung function after curative radiotherapy
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years old * Current lung cancer, not older than 8 weeks * Received written consent * Non small cell lung cancer * Stage IA-IIIA * Inoperable Exclusion Criteria: * Lack of consent * Operable * Additional cancer disease * Small cell lung carcinoma or neuroendocrine lung cancer
References
Publications (0)
Data not yet available